|
Michael Bromley is a Professor in Medical Mycology at the University
of Manchester and is the Director of the Manchester Fungal Infection Group.
His research focuses on drug discovery and drug resistance in fungal
pathogens. While working at F2G Ltd and throughout his academic research
career he has been involved in the evaluation of the antifungal drug
Olorofim. He is currently leading a collaborative project to generate a
genome-scale knockout mutant library in the filamentous fungal pathogen
Aspergillus fumigatus and is developing and employing functional genomics
technologies to understand genetic and environmental drivers of pathogenicity
and drug resistance in fungi. |
No dia 26/04/2024, no Primeiro Encontro Nordestino Microbiologia e Saúde Única que ocorrerá no Centro de Biociências da UFRN, terá a apresentação da palestra: Antifungal drug resistance: An inevitable consequence of evolution, das 09h15min ás 10min.